Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

Aragen Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Post An Enquiry

German Biotechnology Days 2021

Participation Not Confirmed

Update your events

Aragen Announces Expansion of Research Agreement with Boehringer Ingelheim

Lead Product(s): Xentuzumab,Everolimus,Exemestane

Therapeutic Area: Oncology Product Name: BI 836845

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 29, 2021

Details:

Xentuzumab* (BI 836845) is a humanized immunoglobulin G (IgG) 1 monoclonal antibody (mAb) that targets insulin-like growth factor (IGF) ligands IGF-1 and IGF-2 for treatment of breast cancer.